Document 0545
 DOCN  M9650545
 TI    Functional activities of 20 human immunodeficiency virus type 1
       (HIV-1)-specific human monoclonal antibodies.
 DT    9605
 AU    Forthal DN; Landucci G; Gorny MK; Zolla-Pazner S; Robinson WE Jr;
       Department of Medicine, University of California, Irvine College; of
       Medicine, Orange 92668, USA.
 SO    AIDS Res Hum Retroviruses. 1995 Sep;11(9):1095-9. Unique Identifier :
       AIDSLINE MED/96089216
 AB    Antibodies that are useful in the treatment of HIV infection should
       result in virus neutralization or lysis of infected cells but should not
       enhance infection. In this study, the potential clinical use of 20
       HIV-1-specific human monoclonal antibodies (HuMAbs) was determined by
       measuring their enhancing (C-ADE) activities using HIVLAI as the target
       virus. Two HuMAbs mediated both C-ADE and ADCC, two exclusively
       neutralized, and five exclusively mediated ADCC. Ten HuMAbs demonstrated
       no activity in any of the three assays. Three antibodies that
       neutralized HIVLAI were tested against HIVSF2; all three also
       neutralized HIVSF2. Four of five HuMAbs mediating ADCC against HIVLAI
       that were also tested against HIVSF2 had ADCC activity against HIVSF2.
       These results demonstrate that many HuMAbs have unique functions,
       allowing the separation of potentially beneficial and harmful
       activities. Combinations of HuMAbs with ADCC and neutralizing functions
       may have therapeutic utility.
 DE    Antibodies, Monoclonal/*PHARMACOLOGY/THERAPEUTIC USE  Antibody
       Specificity  Antibody-Dependent Cell Cytotoxicity  Cell Line
       Complement/METABOLISM  Human  HIV Antibodies/*PHARMACOLOGY/THERAPEUTIC
       USE  HIV Infections/IMMUNOLOGY/THERAPY  HIV-1/*IMMUNOLOGY
       Neutralization Tests  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).